Advertisement
Clinical Trials
Subscribe to Clinical Trials
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Melanoma Survival Better With Immune Booster

November 5, 2014 1:11 pm | News | Comments

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50% longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by Dana-Farber Cancer Institute scientists. Read more...

GSK Submits European, US Filings for Asthma Med

November 5, 2014 10:14 am | News | Comments

GlaxoSmithKline announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for approval as a maintenance treatment for patients with severe eosinophilic asthma. Read more...          

BRCA-Targeting Drugs Could Treat Prostate Cancer

November 5, 2014 9:31 am | News | Comments

A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer. Read more...               

Advertisement

Using Real-World Data for Outcomes Research and Comparative Effectiveness Studies

November 4, 2014 10:17 am | by Christina Mack, Ph.D., MSPH, Associate Director, Epidemiology, Real-World & Late Phase Research, Quintiles, and Kathy Lang, Ph.D., Senior Director, Emerging Businesses Data & Analytics, Real-World & Late Phase Research, Quintiles | Articles | Comments

Biopharma is increasingly harnessing the power of data collected outside of a controlled clinical environment to generate valuable insights to support products throughout their lifecycle. Read more...

First Human Clinical Trial of 'C dots' Highlights Safety

October 31, 2014 2:14 pm | News | Comments

A first clinical trial of these ultrasmall, multifunctional particles has deemed them safe for humans and cleared easily by the body. Read more...                   

Special Report: Many Stem Cell Clinical Trials for Macular Degeneration

October 31, 2014 11:22 am | by Cynthia Fox, Science Editor | Articles | Comments

The most potent stem cells are coming to patients after helping blind (and nearly blind) mice see for years. Read more...                                                                                

NeuroDerm Announces Positive Phase 2 Results of Parkinsons Vaccine

October 30, 2014 9:49 am | News | Comments

NeuroDerm announced positive phase 2 results for a new Parkinsons vaccine. Read more...                             

ESMO: Cancer Immunotherapy on the Road

October 29, 2014 12:20 pm | by Neil Canavan | Articles | Comments

Since cancer immunotherapy was declared the Breakthrough of the Year in 2013 by Science magazine the field has been on fire, and its relatively few experts have been on the run– explaining the nascent technology and related data to oncologists at venues from the April meeting of AACR in San Diego, to the June meeting of ASCO in Chicago, to the September meeting of ESMO in Madrid.  Read more...

Advertisement

Scripps MS Drug Candidate Shows Promise for UC

October 28, 2014 12:10 pm | News | Comments

Positive new clinical data were released on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute. Read more...              

New Trial Will Explore Heart Disease Prevention in People with HIV

October 28, 2014 9:44 am | News | Comments

The National Institutes of Health and The National Heart, Lung and Blood Institute are initiating a landmark multimillion dollar outcomes trial utilizing pitavastatin for the primary prevention of cardiovascular disease in persons infected with HIV. Read more... 

BMS Acquires Worldwide Rights For New Breast Cancer Therapy

October 28, 2014 8:57 am | News | Comments

Bristol-Myers Squibb Company entered into an agreement F-star Alpha to acquire the company and gain worldwide rights to a targeted therapy that can treat breast and gastric cancer. Read more...           

Baxter Announces FDA Approval For New Hemophilia Drug

October 24, 2014 12:27 pm | News | Comments

Baxter International Inc. announced that the FDA has approved Obizur for the treatment of bleeding episodes in adults with acquired hemophilia A. Read more...                           

Study Finds Best Way to Treat Neck Pain

October 24, 2014 10:03 am | News | Comments

A multicenter study of 169 men and women with a common form of neck pain suggests that both spinal steroid injections and conservative treatment with physical therapy and painkillers work equally well to relieve pain in the short term. Read more...  

Advertisement

NIH Begins Early Human Clinical Trial of New Ebola Vaccine

October 22, 2014 2:00 pm | News | Comments

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. Read more...                

Oramed Gets Positive Data From Oral Insulin Trial

October 22, 2014 10:03 am | News | Comments

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, reported positive top-line clinical results from its Phase 2a clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. Read more...

Neurocrine Announces Phase 3 Study for Inhibitor

October 21, 2014 2:40 pm | News | Comments

Neurocrine Biosciences Inc. announced that it has initiated a Phase 3 clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854.  Read more...                    

Lilly's Diabetes Treatment Receives NDA

October 21, 2014 2:19 pm | News | Comments

FDA has accepted the filing of a NDA for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Read more...       

RegeneRx Proceeds With Phase 3 Eye Drop Study

October 21, 2014 10:43 am | News | Comments

RegeneRx announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea. Read more...

Boehringer Ingelheim Initiates Phase 3 Cancer Study

October 21, 2014 10:34 am | News | Comments

Boehringer Ingelheim announced enrollment of the first patient in a new global Phase 3 study in patients with mCRC. Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed each year. Read more...

New Class of Drugs Shows Promise for Treating Chronic Diarrhea

October 21, 2014 10:23 am | News | Comments

A pilot study testing a new type of drug in patients with chronic diarrhea has shown promising effects on reducing their symptoms. Read more...                                    

Chimerix Gets FDA OK to Test Drug for Ebola

October 17, 2014 1:34 pm | News | Comments

A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration. Read more...

AbbVie Announces Results for HS Treatment

October 17, 2014 1:21 pm | News | Comments

AbbVie announced new results from PIONEER 2, a pivotal Phase 3 study, demonstrating the effect of Humira (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. Read more...

A Novel Approach to Alzheimer’s Disease

October 17, 2014 9:57 am | by Daniel L. Alkon, M.D.,Chief Scientific Officer, Neurotrope Inc. and Toyota Chair in Neurodegenerative Disease, Scientific Director and Professor, Blanchette Rockefeller Neurosciences Institute | Articles | Comments

Alzheimer's disease (AD) afflicts more than 5 million people in the U.S. and 40 million worldwide, generating annual healthcare costs that exceed $200 billion in the U.S. and $600 billion globally. By 2050, AD is expected to strike more than 115 million patients per year, according to the Alzheimer’s Association. Read more...

Personalized Cellular Therapy Achieves Remission in Leukemia Patients

October 16, 2014 12:36 pm | News | Comments

Ninety percent of children and adults with ALL who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. Read more...

Reversing Idiopathic Pulmonary Fibrosis

October 15, 2014 10:14 am | by Cynthia Fox, Science Editor | News | Comments

Lethal fibrosis in lungs of idiopathic pulmonary fibrosis (IPF) mouse models can be reversed, say Yale University researchers. Read more...                                      

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading